TY - JOUR
T1 - Management of conjunctival malignant melanoma
T2 - A review and update
AU - Wong, James R.
AU - Nanji, Afshan A.
AU - Galor, Anat
AU - Karp, Carol L.
N1 - Funding Information:
(DOD-Grant#W81XWH-09-1-0675), The Ronald and Alicia Lepke Grant, The Lee and Claire Hager Grant, The Jimmy and Gaye Bryan Grant. Galor is supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development’s Career Development Award CDA-2- 024-10S. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Funding Information:
The authors were supported by NIH Center Core Grant P30EY014801, Research to Prevent Blindness Unrestricted Grant, Department of Defense
PY - 2014/6
Y1 - 2014/6
N2 - Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, risk factors, presentation, diagnosis, management, prognosis, staging, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.
AB - Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, risk factors, presentation, diagnosis, management, prognosis, staging, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.
KW - BRAF inhibitors
KW - Conjunctival malignant melanoma
KW - Dabrafenib
KW - IFNa-2b
KW - Ipilimumab
KW - Melanoma mitomycin C
KW - Ocular neoplasm
KW - Vemurafenib
UR - http://www.scopus.com/inward/record.url?scp=84901254588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901254588&partnerID=8YFLogxK
U2 - 10.1586/17469899.2014.921119
DO - 10.1586/17469899.2014.921119
M3 - Review article
AN - SCOPUS:84901254588
VL - 9
SP - 185
EP - 204
JO - Expert Review of Ophthalmology
JF - Expert Review of Ophthalmology
SN - 1746-9899
IS - 3
ER -